Identifying low-burden TP53 mutations with NGS in CLL

Florence Cymbalista, MD, Hôpital Avicenne, Bobigny, France, comments on the use of next-generation sequencing (NGS) to identify low-burden TP53 mutations in patients with chronic lymphocytic leukemia (CLL) and use it as a tool for early diagnosis and treatment. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.